Intravitreal erythropoietin injection for the treatment of non-arteritic anterior ischaemic optic neuropathy

Modarres, Mehdi; Falavarjani, Khalil Ghasemi; Nazari, Hossein; Sanjari, Mostafa Soltan; Aghamohammadi, Farzaneh; Homaii, Mohsen; Samiy, Nasrollah

doi:10.1136/bjo.2010.191627

Cited by 56 publications

(40 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…65 Visual acuity improved in 61% of patients and maintained for up to 3 months before deteriorating back to baseline. 65 However, there was no improvement observed in the retina for a group of patients with acute vascular occlusion. 66 In human, these clinical trials and case studies will help to establish the safety and effectiveness of EPO with regard to the optimal dosage and regime for the different ocular disorders.…”

Section: Current Clinical Trialsmentioning

confidence: 91%

“…EPO therapy was also evaluated in a small group of subjects with non-arteritic anterior ischemic optic neuropathy. 65 A single dose of intravitreal injection (2000 U) was given and patients were followed up to 6 months post injection. 65 Visual acuity improved in 61% of patients and maintained for up to 3 months before deteriorating back to baseline.…”

Section: Current Clinical Trialsmentioning

confidence: 99%

“…65 A single dose of intravitreal injection (2000 U) was given and patients were followed up to 6 months post injection. 65 Visual acuity improved in 61% of patients and maintained for up to 3 months before deteriorating back to baseline. 65 However, there was no improvement observed in the retina for a group of patients with acute vascular occlusion.…”

Section: Current Clinical Trialsmentioning

confidence: 99%

“…66 In human, these clinical trials and case studies will help to establish the safety and effectiveness of EPO with regard to the optimal dosage and regime for the different ocular disorders. 58,62,64,65 However, further human studies are needed before the EPO becomes fully established for treatment of ocular disorders.…”

Section: Current Clinical Trialsmentioning

confidence: 99%

“…66 Intravitreal mode of administration had been widely studied and used both in pre-clinical and clinical trials for EPO therapy. 65,66,80,81 In intravitreal injections, the injected formulations will affect the dosage and regime used. If the EPO formulation has a rapid clearance, it would be ideal for repeated injections when needed.…”

Section: Administration Of Epo Therapy For Ocular Disordersmentioning

confidence: 99%

See 4 more Smart Citations

Revisiting the role of erythropoietin for treatment of ocular disorders

Ding

Leow

Munisvaradass

et al. 2016

Eye

View full text Add to dashboard Cite

Erythropoietin (EPO) is a glycoprotein hormone conventionally thought to be responsible only in producing red blood cells in our body. However, with the discovery of the presence of EPO and EPO receptors in the retinal layers, the EPO seems to have physiological roles in the eye. In this review, we revisit the role of EPO in the eye. We look into the biological role of EPO in the development of the eye and the physiologic roles that it has. Apart from that, we seek to understand the mechanisms and pathways of EPO that contributes to the therapeutic and pathological conditions of the various ocular disorders such as diabetic retinopathy, retinopathy of prematurity, glaucoma, age-related macular degeneration, optic neuritis, and retinal detachment. With these understandings, we discuss the clinical applications of EPO for treatment of ocular disorders, modes of administration, EPO formulations, current clinical trials, and its future directions.

show abstract

Section: Current Clinical Trialsmentioning

confidence: 91%

Section: Current Clinical Trialsmentioning

confidence: 99%